ERBB2 and breast cancer: Regarding endocrine therapy, the everolimus (Afinitor®, Eve) + exemestane (Aromasin®, Exe) combination is indicated in postmenopausal patients with advanced HR-positive, HER2-negative BC after recurrence or progression following treatment with non-steroidal aromatase inhibitors [10–13].